Physician profile
Celia E Dominguez
NPI 1508895210
$8,485.75
in general payments reported to CMS, 2019-2025
25 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Reproductive Endocrinology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,836 · 2020: $413 · 2021: $4,989 · 2022: $392 · 2023: $376 · 2024: $279 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837 · Education: $19.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.64 |
| Education | $19.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,795.91 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Ferring Pharmaceuticals INC. | $564.29 | 2019-2025 | Menopur |
| Biohaven Pharmaceuticals, INC. | $471.04 | 2021 | |
| Covidien Lp | $407.88 | 2019 | |
| Organon LLC | $345.33 | 2021-2024 | Follistim Aq, Ganirelix Acetate |
| Hologic Sales and Service, LLC | $330.90 | 2019-2023 | Omni Hysteroscope, Myosure Tissue Removal Device |
| Amarin Pharma, INC. | $291.89 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $280.19 | 2019-2021 | |
| Emd Serono, INC. | $145.57 | 2019-2023 | |
| Roche Diagnostics Corporation | $135.49 | 2019-2021 | |
| Exeltis, USA INC. | $119.76 | 2024-2025 | Slynd |
| Aspira Women'S Health INC | $112.02 | 2022-2023 | Ova1 |
| Gen-Probe Sales & Service, INC. | $102.14 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.60 | 2020-2021 | |
| Myovant Sciences INC. | $42.71 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $42.26 | 2025 | Exparel, Iovera |
| Sumitomo Pharma America, INC. | $39.00 | 2023 | Myfembree |
| Therapeuticsmd, INC. | $35.75 | 2022 | |
| Astellas Pharma US INC | $29.08 | 2024 | Veozah |
| Myriad Genetic Laboratories, INC. | $28.18 | 2021 | |
| Sanofi Pasteur INC. | $25.54 | 2023 | |
| Lilly USA, LLC | $24.93 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.52 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.99 | 2025 | |
| Merz North America, INC. | $16.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celia Dominguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.